Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies

详细信息    查看全文

• 作者：Kelly J. Norsworthy ; MD^a ; Eunpi Cho ; MD^a ; ¹ ; Jyoti Arora ; MSc^b ; ² ; Jeanne Kowalski ; PhD^b ; Hua-Ling Tsai ; ScM^a ; Erica Warlick ; MD^a ; ³ ; Margaret Showel ; MD^a ; Keith W. Pratz ; MD^a ; Lesley A. Sutherland ; MD^a ; ⁴ ; Steven D. Gore ; MD^a ; ⁵ ; Anna Ferguson ; RN BSN^a ; Sarah Sakoian ; RN^a ; Jackie Greer ; RN^a ; Igor Espinoza-Delgado ; MD^c ; ⁶ ; Richard J. Jones ; MD^a ; William H. Matsui ; MD^a ; B. Douglas Smith ; MD^a ; ^{bdsmith@jhmi.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Differentiation ; Acute myeloid leukemia ; Myelodysplastic syndrome ; Bexarotene ; Entinostat
• 刊名：Leukemia Research
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：49
• 期：Complete
• 页码：90-97
• 全文大小：1189 K

文摘

<dl class="listitem" id="list_lis0005"><dt class="label">•dt><dd>

d="par0005">Myeloid growth factors enhance the leukemic activity of differentiation agents in vitro.

dd><dt class="label">•dt><dd>

d="par0010">GM-CSF plus either bexarotene or entinostat demonstrated differentiation activity in heavily pretreated AML and MDS.

dd><dt class="label">•dt><dd>

d="par0015">GM-CSF in combination with either bexarotene or entinostat has an acceptable toxicity profile in previously treated AML and MDS.

dd>dl>